Senseonics Holdings, Inc.

Senseonics Holdings, Inc. is a medical technology company dedicated to the development, manufacturing, and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. The company's mission is to transform lives within the global diabetes community through its differentiated, long-term implantable glucose management technology. Headquartered in Germantown, Maryland, Senseonics focuses on providing innovative solutions for diabetes management. [2, 5, 8, 9, 10, 21, 22, 28, 34]

The company's primary product line includes the Eversense, Eversense XL, Eversense E3, and Eversense 365 implantable CGM systems. These systems measure glucose levels via a small sensor inserted under the skin, which communicates with a removable and rechargeable smart transmitter worn over the sensor, and a mobile application for real-time data monitoring. A key differentiator is the extended wear time of its sensors, with Eversense 365 being the world's first and only one-year implantable CGM, significantly reducing the frequency of sensor changes compared to other systems. [2, 5, 8, 9, 10, 20, 21, 28, 30]

In recent developments, Senseonics announced an $80 million public offering of common stock and pre-funded warrants on April 30, 2026, to support the ongoing launch of Eversense 365 and future product development. [9, 11, 19, 22, 23, 33] The company also initiated the European launch of Eversense 365 in April 2026, following its CE Mark approval in January 2026 and U.S. FDA approval in September 2024. [20] Furthermore, Senseonics is transitioning to a self-commercialization model for Eversense 365, taking over global sales and marketing from its partner Ascensia Diabetes Care starting January 1, 2026, a strategic move aimed at accelerating growth and improving gross margins. [26, 29] Timothy T. Goodnow serves as the President, CEO, and Director of Senseonics Holdings, Inc. [2, 6, 8, 12, 15]